News, Press Release James McIlroy News, Press Release James McIlroy

EnteroBiotix receives MHRA MIA (IMP) licensure of state-of-the-art GMP manufacturing facility for producing microbiome therapeutics

EnteroBiotix today announced that it has been granted a Manufacturer’s licence for Investigational Medicinal Products (IMP) by the Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture microbiome product candidates for clinical trials. The facility also incorporates an in-house QC hub and analytical department.

Read More
Press Release James McIlroy Press Release James McIlroy

EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline

Glasgow, Scotland – 7th September 2021 – EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development and manufacturing capabilities.

Read More

Find out more about our donor programme. Visit Number2.org